-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Downgrades IGM Biosciences to Hold, Lowers Price Target to $2.5

Benzinga·01/10/2025 16:55:20
Listen to the news
Stifel analyst Stephen Willey downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Hold and lowers the price target from $27 to $2.5.